AstraZeneca entered into an exclusive global license agreement with China’s Dizal Pharmaceutical for the lung cancer treatment.
Source link
About The Author
AstraZeneca Enters Exclusive License Deal For Lung Cancer Drug Zegfrovy For Up to $1.5 Billion